Antimicrobial Dosing in Acute Renal Replacement

被引:30
作者
Fissell, William H. [1 ]
机构
[1] Vanderbilt Univ, Dept Hypertens & Nephrol, Nashville, TN 37232 USA
基金
美国国家卫生研究院;
关键词
Acute kidney injury; Continuous renal replacement therapy; Hemodialysis; Sustained low-efficiency dialysis; Antimicrobial agents; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; ACUTE KIDNEY INJURY; GLOMERULAR-FILTRATION-RATE; MIDDLE-MOLECULE CLEARANCE; INTENSIVE-CARE PATIENTS; CONTINUOUS-INFUSION; IN-VITRO; PIPERACILLIN-TAZOBACTAM; BETA-LACTAMS;
D O I
10.1053/j.ackd.2012.10.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Acute kidney injury (AKI) is a common problem in hospitalized patients and is associated with significant morbidity and mortality. Two large trials showed no benefit from increased doses of renal replacement therapy (RRT) despite previous clinical data suggesting that increased clearance from RRT has beneficial effects. Since infection is the leading cause of death in AKI, my group and others hypothesized that increased RRT antibiotic clearance might create a competing morbidity. The data from my group, as well as those of other groups, show that many patients are underdosed when routine "1 size fits all" antibiotic dosing is used in patients with AKI receiving continuous RRT (CRRT). Here, concepts of drug distribution and clearance in AKI are briefly discussed and then 1 antibiotic (piperacillin) is discussed in depth to illustrate the challenges in applying the medical literature to clinical practice. The fact that published data on drug dosing in AKI and dialysis reflect the evolution of practice patterns and often do not apply to present prescribing habits is also discussed. A more general approach to drug dosing facilitates situation-specific prescribing by the nephrologist and critical care specialist. (C) 2013 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 77 条
[1]   Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines [J].
Agwuh, Kenneth N. ;
MacGowan, Alasdair .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :256-265
[2]   Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].
Andes, D ;
Marchillo, K ;
Conklin, R ;
Krishna, G ;
Ezzet, F ;
Cacciapuoti, A ;
Loebenberg, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142
[3]  
[Anonymous], 1999, Drug Prescribing in Renal Failure
[4]   Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia [J].
Antachopoulos, Charalampos ;
Meletiadis, Joseph ;
Sein, Tin ;
Roilides, Emmanuel ;
Walsh, Thomas J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :321-328
[5]  
Aronoff G.R., 2007, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, V5th
[6]   Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous Venovenous Hemofiltration [J].
Arzuaga, A ;
Maynar, J ;
Gascón, AR ;
Isla, A ;
Corral, E ;
Fonseca, F ;
Sánchez-Izquierdo, JA ;
Rello, J ;
Canut, A ;
Pedraz, JL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :168-176
[7]   Association of fluconazole pharmacodynamics with mortality in patients with candidemia [J].
Baddley, John W. ;
Patel, Mukesh ;
Bhavnani, Sujata M. ;
Moser, Stephen A. ;
Andes, David R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3022-3028
[8]   Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT [J].
Bauer, Seth R. ;
Salem, Charbel ;
Connor, Michael J. ;
Groszek, Joseph ;
Taylor, Maria E. ;
Wei, Peilin ;
Tolwani, Ashita J. ;
Fissell, William H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (03) :452-457
[9]  
Baxter Healthcare, 2007, CYCL INJ USP
[10]  
Bedford L, 2001, VINBLASTINE SULFATE